Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
1.
Cardiol Rev ; 27(1): 34-40, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-29570476

RESUMEN

Patent foramen ovale (PFO), an embryonic remnant of the fetal circulation, is present in 20-25% of adults. Although recent observational studies and clinical trials have established the link between PFO-mediated right-to-left shunting with cryptogenic stroke and migraine with aura, the role of a PFO in exacerbating hypoxemic medical conditions (ie, sleep apnea, chronic obstructive pulmonary disease, pulmonary hypertension, platypnea-orthodeoxia, pulmonary arteriovenous malformation, high-altitude pulmonary edema, and exercise desaturation) remains less understood. PFO-mediated hypoxemia occurs when deoxygenated venous blood from the right atrium enters and mixes with oxygenated arterial blood in the left atrium. Patients with an intracardiac right-to-left shunt may have profound hypoxemia out of proportion to underlying primary lung disease, even in the presence of normal right-sided pressures. The presence of right-to-left cardiac shunting can exacerbate the degree of hypoxemia in patients with underlying pulmonary disorders. In a subset of these patients, percutaneous PFO closure may result in marked improvement in dyspnea and hypoxemia. This review discusses the association between PFO-mediated right-to-left shunting with medical conditions associated with hypoxemia and explores the role of percutaneous PFO closure in alleviating the hypoxemia.


Asunto(s)
Foramen Oval Permeable/complicaciones , Hipoxia/etiología , Procedimientos Endovasculares , Foramen Oval Permeable/diagnóstico por imagen , Foramen Oval Permeable/cirugía , Humanos
2.
Turk J Anaesthesiol Reanim ; 46(1): 72, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30140508
3.
J Correct Health Care ; 24(4): 337-341, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30126314

RESUMEN

The effect of incarceration on sepsis outcomes in the United States is infrequently described in the literature. This study sought to investigate whether being incarcerated affected mortality rates in sepsis. The retrospective study used data from October 1, 2013, to November 30, 2016, of patients admitted with a diagnosis of sepsis at a tertiary care center with a primary outcome of in-hospital mortality. The study cohort included 8,568 cases of sepsis, of which 8,448 were noninmates and 120 were inmates. Overall mortality was 15.7%; for noninmates, the rate was 15.3%, and for inmates, 42.5%. The risk of death among inmates was 2.8 times that of noninmates. Neither age, sex, nor race were significant confounders. Findings suggest a direct association between incarceration and sepsis mortality. Larger regional or nationwide case-control studies should be conducted to confirm these findings.


Asunto(s)
Mortalidad Hospitalaria , Prisiones/estadística & datos numéricos , Sepsis/mortalidad , Adulto , Femenino , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Estados Unidos/epidemiología
5.
Chest ; 153(4): e89-e91, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29626975

RESUMEN

CASE PRESENTATION: A 77-year-old woman presented to the hospital with symptoms of progressive shortness of breath with associated right-sided pleuritic pain. The patient had begun noting dyspnea on exertion, limiting her ability to go on hikes over the few days prior to admission. Her medical history is significant for carcinoid tumor status postresection in 2012 without recurrence. She has no history of thromboembolism or clotting disorders, and she has no history of smoking or drug abuse. Current medications include amlodipine, celecoxib, hydrochlorothiazide, and rosuvastatin.


Asunto(s)
Enfermedad Veno-Oclusiva Pulmonar/complicaciones , Trombosis de la Vena/complicaciones , Enfermedad Aguda , Anciano , Dolor en el Pecho/etiología , Disnea/etiología , Ecocardiografía , Inhibidores del Factor Xa/uso terapéutico , Femenino , Humanos , Enfermedad Veno-Oclusiva Pulmonar/diagnóstico por imagen , Enfermedad Veno-Oclusiva Pulmonar/tratamiento farmacológico , Rivaroxabán/uso terapéutico , Tomografía Computarizada por Rayos X , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/tratamiento farmacológico
8.
J Intensive Care Med ; 33(2): 87-96, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28299952

RESUMEN

OBJECTIVE: To review the data surrounding the utility of N-acetylcysteine (NAC) in sepsis and identify areas needed for additional research. DATA SOURCES: A review of articles describing the mechanisms of action and clinical use of NAC in sepsis. SUMMARY OF REVIEW: Despite many advances in critical care medicine, still as many as 50% of patients with septic shock die. Treatments thus far have focused on resuscitation and restoration of macrocirculatory targets in the early phases of sepsis, with less focus on microcirculatory dysfunction. N-acetylcysteine, due to its anti-inflammatory and antioxidative properties, has been readily investigated in sepsis and has yielded largely incongruous and disappointing results. In addition to its known anti-inflammatory and antioxidative roles, one underappreciated property of NAC is its ability to vasodilate the microcirculation and improve locoregional blood flow. Some investigators have sought to capitalize on this mechanism with promising results, as evidenced by microcirculatory vasodilation, improvements in regional blood flow and oxygen delivery, and reductions in lactic acidosis, organ failure, and mortality. CONCLUSION: In addition to its antioxidant and anti-inflammatory properties, N-acetylcysteine possesses vasodilatory properties that could benefit the microcirculation in sepsis. It is imperative that we investigate these properties to uncover NAC's full potential for benefit in sepsis.


Asunto(s)
Acetilcisteína/uso terapéutico , Depuradores de Radicales Libres/uso terapéutico , Microcirculación/fisiología , Sepsis/tratamiento farmacológico , Acidosis Láctica/etiología , Humanos , Mortalidad , Insuficiencia Multiorgánica/etiología , Flujo Sanguíneo Regional , Sepsis/complicaciones , Sepsis/mortalidad , Sepsis/fisiopatología , Vasodilatación
9.
JAMA ; 318(22): 2259, 2017 12 12.
Artículo en Inglés | MEDLINE | ID: mdl-29234804
10.
Turk J Anaesthesiol Reanim ; 45(5): 313-317, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29114418

RESUMEN

Hypersensitivity pneumonitis (HSP) is a rare syndrome characterised by granulomatous inflammatory lung disease due to repeated sensitisation from a specific antigen. We present the case of a 61-year old male veteran with a history of nodular eczema who presented with 2 weeks of progressive dyspnoea on exertion and pleuritic chest pain. The patient was started on ustekinumab 5 weeks prior to presentation. Initial workup revealed ground-glass opacities on computed tomography (CT) scan of the chest. Cardiac workup was unrevealing with a normal myocardial perfusion stress test. The patient was started on inhaled corticosteroids and albuterol for reactive airway disease. Due to the persistence of symptoms despite treatment, the patient underwent bronchoscopy with bronchoalveolar lavage (BAL), transbronchial biopsy and endobronchial ultrasound-guided biopsy (EBUS). Bronchoscopy showed normal appearing airways of both right and left lungs. The BAL was remarkable for chronic inflammation and pulmonary macrophages. The BAL cell count differential was 1% granulocytes, 50% lymphocytes, 17% eosinophils and 32 mononuclear cells. The pathology from the mediastinal lymph nodes showed reactive inflammatory cells and no malignancy. The pathology from the transbronchial biopsy of the anterior basilar segment of the right lower lobe showed organising pneumonia with occasional ill-defined granulomas that stained negative for Acid Fast Bacilli (AFB) and Grocott's methenamine (GMS) appeared to be consistent with hypersensitivity pneumonitis. Based on the pathological diagnosis of HSP, the patient was managed with discontinuation of ustekinumab, with subsequent improvement of his symptoms. To our knowledge, this is the first report suggesting ustekinumab, like other biological therapies, has the potential to cause HSP.

11.
Pulm Circ ; 7(4): 797-802, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29168664

RESUMEN

Adult-onset Still's disease (AOSD) is an inflammatory disorder characterized by recurrent fevers, arthralgia, leukocytosis, and a salmon-colored rash. Diagnosis is made based on the Yamaguchi criteria. Various cardiac and pulmonary manifestations have been described in association with AOSD, including acute respiratory distress syndrome (ARDS) and pulmonary arterial hypertension (PAH). We describe the first case of both PAH and ARDS in a patient with AOSD who, despite aggressive therapy, declined rapidly and ultimately died. There was concern for pulmonary veno-occlusive disease given the rate of her decompensation, but this was found not to be the case on autopsy. Treatment of AOSD with cardiopulmonary involvement requires rapid identification of AOSD followed by aggressive immunosuppression.

12.
Gastroenterology Res ; 10(4): 235-237, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28912909

RESUMEN

BACKGROUND: Tranexamic acid (TXA) may be beneficial in the management of upper gastrointestinal bleeding (UGIB). We sought to investigate how frequently intensivists at our academic institution use TXA for patients with UGIB, and to investigate whether the utilization rate of TXA differs between surgical and medical intensivists, and provide an updated literature review on the subject. METHODS: We performed a retrospective cohort study of patients admitted for UGIB to the surgical intensive care unit (SICU) and the medical intensive care unit (MICU) at our academic healthcare facility (University of Florida Health - Shands Hospital) from January 1, 2013 to December 31, 2016. The patients were categorized as receiving or not receiving TXA. The overall utilization rate of TXA was calculated, and the utilization rates for the MICU and SICU were compared using a two-sample test for equality of two proportions with continuity correction. RESULTS: The study cohort included a total of 1,829 patients with a diagnosis of UGIB. Of those, 988 were treated in the MICU and 841 were treated in the SICU. Of the 988 patients in the MICU, six received TXA (0.61%), while 10 (1.19%) of the 841 patients in the SICU received TXA. The overall utilization rate of TXA was 0.87%. The odds of receiving TXA in the SICU were 1.97 times greater than in the MICU (odds ratio (OR): 1.97, 95% confidence interval (CI): 0.74 - 5.2, P = 1.83). CONCLUSIONS: Our study suggests that TXA may be underused in the management of UGIB, and that the utilization rate does not differ significantly between surgical and medical intensivists.

17.
18.
N Engl J Med ; 376(21): 2096, 2017 05 25.
Artículo en Inglés | MEDLINE | ID: mdl-28541027
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA